

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:18:25 ON 29 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 28 AUG 2006 HIGHEST RN 904961-01-9
 DICTIONARY FILE UPDATES: 28 AUG 2006 HIGHEST RN 904961-01-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\10809636gt.str

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



G1 O,S

G2 CH₂,CH,A,Ak

G3 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 15:18:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16091 TO ITERATE

12.4% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 314223 TO 329417
PROJECTED ANSWERS: 0 TO 0
```

L2 0 SEA SSS SAM L1

```
=> s 11 sss full
FULL SEARCH INITIATED 15:18:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 321692 TO ITERATE
```

```
100.0% PROCESSED 321692 ITERATIONS 32 ANSWERS
SEARCH TIME: 00.00.10
```

L3 32 SEA SSS FUL L1

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	166.94	167.15

```
FILE 'CAPLUS' ENTERED AT 15:19:06 ON 29 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Aug 2006 VOL 145 ISS 10
FILE LAST UPDATED: 28 Aug 2006 (20060828/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 13
L4 7 L3
```



=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:247321 CAPLUS
 DOCUMENT NUMBER: 134:280852
 TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
 INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
 PATENT ASSIGNEE(S): Merck Patent GmbH, Germany; et al.
 SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023365	A1	20010405	WO 2000-EP8940	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385921	AA	20010405	CA 2000-2385921	20000913
BR 2000014294	A	20020521	BR 2000-14294	20000913
EP 1216235	A1	20020626	EP 2000-965991	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6890930	B1	20050510	US 2002-89166	20000913
NO 2002001502	A	20020326	NO 2002-1502	20020326
PRIORITY APPLN. INFO.:			US 1999-407958	A 19990928
			US 1999-287586P	P 19990928
			WO 2000-EP8940	W 20000913

OTHER SOURCE(S): MARPAT 134:280852

GI




AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH₂Ar, Hal, NH₂, NHA, NA₂, NO₂, cyano, COR₂, CONH₂, CONHA, CONA₂, CO₂H, CO₂A, SO₂A; R₂, R₃ = H, A, C(:NH)NH₂, solid phase; R₄ = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C₂-4 alkylene; Z = bond, phenylene; A = (un)branched C₁-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n = 1-3; m = 0-3; with a variety of provisos]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, 3-(aminomethyl)benzylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R₄CHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF₃CO₂H, gave a variety of compds. I, e.g., the preferred compound II.

IT 332363-12-9P, 3-(3-Aminomethylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one
 332363-13-0P, 3-(3-Aminomethylbenzyl)-2-[2-(4-dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate)


RN 332363-12-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



RN 332363-13-0 CAPLUS

CN 4 (3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-[2-[(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:247320 CAPLUS

DOCUMENT NUMBER: 134:280851

TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders

INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany; et al.

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023364	A1	20010405	WO 2000-EP8939	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2385918 AA 20010405 CA 2000-2385918 20000913
 BR 2000014311 A 20020521 BR 2000-14311 20000913
 EP 1216233 A1 20020626 EP 2000-962482 20000913
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 NO 2002001503 A 20020326 NO 2002-1503 20020326
 US 7060706 B1 20060613 US 2002-89167 20020829
 PRIORITY APPLN. INFO.: US 1999-407939 A 19990928
 US 1999-325777P P 19990928
 WO 2000-EP8939 W 20000913
 OTHER SOURCE(S): MAPPAT 134-280851

OTHER SOURCE(S) : MARPAT 134:280851

GI



AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH₂Ar, Hal, NH₂, NHA, NA₂, NO₂, cyano, COR₂, CONH₂, CONHA, CONA₂, CO₂H, CO₂A, SO₂A; R₂, R₃ = H, A, C(:NH)NH₂, solid phase; R₄ = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C₂-4 alkylene; A = (un)branched C₁-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n, m = 0-3]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, [{3-(aminomethyl)cyclohexyl}methyl]amine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R₄YCHO, oxidation of the resultant



dihydroquinazolinone ring system, and cleavage from the resin with CF₃CO₂H, gave a variety of compds. I, e.g., the preferred compound II.

IT 332121-76-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one
 332121-77-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-methyl-3H-quinazolin-4-one
 332121-78-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one
 332121-79-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-6-methoxy-3H-quinazolin-4-one
 332121-80-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2-(4-dimethylaminophenyl)vinyl]-3H-quinazolin-4-one

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of quinazolinone derivs. as glycoprotein IbIX antagonists)



RN 332121-76-3 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)





RN 332121-77-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-methyl- (9CI) (CA INDEX NAME)





RN 332121-78-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)





RN 332121-79-6 CAPLUS

CN 4 (3H)-Quinazolinone, 3-[[3-[(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-methoxy- (9CI) (CA INDEX NAME)



RN 332121-80-9 CAPLUS

CN 4 (3H)-Quinazolinone, 3-[[3-[(aminomethyl)cyclohexyl]methyl]-2-[2-[4-(dimethylamino)phenyl]ethenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:12269 CAPLUS

DOCUMENT NUMBER: 124:175225
 TITLE: Electron impact-promoted fragmentation of some substituted 4-quinazolones
 AUTHOR(S): Badr, M. Z. A.; Hammerum, Steen; Duffield, A. M.
 CORPORATE SOURCE: Chemistry Department, Assiut Univ., Assiut, Egypt
 SOURCE: Journal of Mass Spectrometry (1995), 30(12), 1701-6
 CODEN: JMSPFJ; ISSN: 1076-5174
 PUBLISHER: Wiley
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Low-resolution mass spectra, and where appropriate complete high-resolution spectra, were recorded for 29 2,3-disubstituted 4-quinazolones. Rationalizations are presented for the principal fragmentation modes of this series of aromatic compds. Four of the 4-quinazolones which contain a vinyl-2-furanyl group attached to C-2 of the heterocyclic ring exhibited an unusual loss of C₃H₂O from their resp. mol. ions.
 IT 56479-05-1
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
 (electron impact-promoted fragmentation of substituted 4-quinazolones)
 RN 56479-05-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1983:143365 CAPLUS
 DOCUMENT NUMBER: 98:143365
 TITLE: Synthesis and antiparkinsonian activity of styryl quinazolones
 AUTHOR(S): Kumar, Pradeep; Nath, C.; Bhargava, K. P.; Shanker, K.
 CORPORATE SOURCE: Dep. Pharmacol. Therapeut., King George's Med. Coll., Lucknow, 226003, India
 SOURCE: Pharmazie (1982), 37(11), 802
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Condensation of acetanthranils I ($R = H, Br, iodo$; $R1 = H, Br$) with $R2C6H4NHNH2$ ($R2 = H, 2\text{-Me}, 4\text{-NO}_2$) gave methylquinazolines II, which condensed with benzaldehydes to give styrylquinazolines III ($R3 = 4\text{-MeO}, 4\text{-NO}_2, Me2N, 3\text{-NO}_2, 2\text{-Cl}, 2\text{-F}$, $R4 = H$; $R3 = 3\text{-Me}, R4 = 4\text{-HO}$; $R3R4 = CH2O2$). Antiparkinsonian activities of III at 100 mg/kg in rats were tested against oxotremorine induced tremors and reserpine induced rigidity. III ($R = R1 = R2 = R3 = H, R4 = 4\text{-MeO}$; $R = Br, R1 = R2 = R3 = H, R4 = 2\text{-Cl}$) possessed maximum activity with a tremor index of 2.4 (control 3.0) and 20% rigidity (control 100%).


IT 85226-44-4P 85226-45-5P 85226-47-7P

85226-48-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiparkinsonian activity of)


RN 85226-44-4 CAPLUS

CN 4 (3H) -Quinazolinone, 2 - [2 - [4 - (dimethylamino)phenyl]ethenyl] -3 - (phenylamino) - (9CI) (CA INDEX NAME)




RN 85226-45-5 CAPLUS


CN 4 (3H) -Quinazolinone, 2 - [2 - [4 - (dimethylamino)phenyl]ethenyl] -3 - [(4 - nitrophenyl)amino] - (9CI) (CA INDEX NAME)




RN 85226-47-7 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[2-[4-(dimethylamino)phenyl]ethenyl]-6-iodo-3-[(4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)



RN 85226-48-8 CAPLUS
 CN 4 (3H)-Quinazolinone, 6-iodo-3-[(2-methylphenyl)amino]-2-[2-(3-nitrophenyl)ethenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1979:611313 CAPLUS
 DOCUMENT NUMBER: 91:211313
 TITLE: Studies on the synthesis of 2,3-disubstituted
 4 (3H)quinazolinone
 AUTHOR(S): Badr, M. Z. A.; El-Sherif, H. A. H.
 CORPORATE SOURCE: Fac. Sci., Univ. Assiut, Assiut, Egypt
 SOURCE: Egyptian Journal of Chemistry (1978), Volume Date
 1976, 19(2), 341-6
 CODEN: EGJCA3; ISSN: 0367-0422
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Quinazolinone derivs. (I; R = Et, Ph, PhCH₂; R₁ = aryl, 2-furyl) were prepared in 80-90% yields by Knoevenagel condensation of II with R₁CHO in


absolute EtOH containing EtONa.
 IT 56479-05-1P 71822-48-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 56479-05-1 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 71822-48-5 CAPLUS
 CN 4 (3H)-Quinazolinone, 2-[2-(3-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-
 (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1975:497193 CAPLUS
 DOCUMENT NUMBER: 83:97193
 TITLE: Synthesis of some benzoxazin-4-ones,
 quinazolin-4-ones, and the related products
 AUTHOR(S): Messiha, N. N.; Abdel-Kader, A. M. M.; Nosseir, M. H.
 CORPORATE SOURCE: Lab. Polym. Pigm., Natl. Res. Cent., Cairo, Egypt
 SOURCE: Indian Journal of Chemistry (1975), 13(4), 326-8
 CODEN: IJOCAP; ISSN: 0019-5103
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 83:97193
 GI For diagram(s), see printed CA Issue.
 AB Benzoxazinones I [R = 2-furyl, p-Me₂NC₆H₄, 3,4-(MeO)(HO)C₆H₃] prepared by condensation of 2-methyl-3,1-benzoxazin-4-one with RCHO, were cleaned with R₁NH₂ to give o-R₁NHCOC₆H₄NHC(=O)CHR (II, R₁ = Me, Et, Bu, PhCH₂, NH₂; R₁ = same as above). Styrylquinazolinones III were prepared by condensation of 2-methyl-3-alkylquinazolin-4-ones with RCHO. III prepared were [R =

3,4-(MeO)(HO)C₆H₃, R₁ = Me, Et; R = 2-furyl, R₁ = Me, PhCH₂]. Treatment of I with NaN₃ gave tetrazoles IV [R = 2-furyl, p-tolyl, 3,4-(MeO)(HO)C₆H₃] and benzimidazoles V (R = same as above, p-Me₂NC₆H₄). II treated with NaNO₂ gave (o-RCH:CHCONHC₆H₄NH)₂CO [R = p-tolyl, 3,4-(MeO)(HO)C₆H₃]. Infrared studies indicated trans-olefin in these products. Uv showed that substituents caused a bathochromic shift increasing in the order p-Me < p-Cl < p-MeO < 3,4-(MeO)(HO) < p-Me₂N.


IT 56479-05-1 56479-06-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(spectral characteristics of)

RN 56479-05-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-
(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 56479-06-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(2-nitrophenyl)ethenyl]-3-(phenylmethyl)-, (E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1974:3464 CAPLUS

DOCUMENT NUMBER: 80:3464

TITLE: Action of Grignard reagents and aryllithium on
3-alkyl-2-styrylquinazol-in-4-ones and
2-styryl-3,1-benzoxazin-4-ones

AUTHOR(S): Messiha, N. N.; Doss, N. L.; Nosseir, M. H.

CORPORATE SOURCE: Lab. Polym. Pigm., Natl. Res. Cent., Cairo, Egypt

SOURCE: Indian Journal of Chemistry (1973), 11(8), 738-40

CODEN: IJOCAP; ISSN: 0019-5103

DOCUMENT TYPE: Journal

LANGUAGE: English


GI For diagram(s), see printed CA Issue.

AB Some derivs. of 2-styryl-3,1-benzoxazin-4-ones (I) and 3-alkyl-2-styrylquinazolin-4-ones (II) were prepared by reaction of the corresponding aldehyde with the ketone. 3-Alkyl- and 3-amino-2-styrylquinazolin-4-ones react sep. with arylmagnesium halides (3 mole equivalent) to give 3-alkyl- and 3-amino-2-(α,α' -diarylethyl)quinazolin-4-ones, resp. With aryllithium, I and II gave α -(cinnamoylamidophenyl)diarylcbinols and 3-alkyl-4,4'-diaryl-2-styrylquinazolines, resp. Structures were assigned on the basis of anal. ir, and uv spectral data.


IT 50830-12-1P 50830-16-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 50830-12-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(4-nitrophenyl)ethenyl]-3-(phenylmethyl)- (9CI)
(CA INDEX NAME)

RN 50830-16-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-(2-nitrophenyl)ethenyl]-3-(phenylmethyl)- (9CI)
(CA INDEX NAME)

=> log y
COST IN U.S. DOLLARS

SINCE FILE
ENTRY

FULL ESTIMATED COST

36.23

TOTAL
SESSION

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

CA SUBSCRIBER PRICE

-5.25

TOTAL
SESSION

STN INTERNATIONAL LOGOFF AT 15:19:26 ON 29 AUG 2006